Meta-Iodobenzylguanidine Iodine-123 and Cardiac Adrenergic Activity in Familial Dilated Cardiomyopathy  by Martins, Elisabete et al.
FJ A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 3 , N O . 9 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 0 . 0 7 . 0 0 4B R I E F R E P O R T
Meta-Iodobenzylguanidine Iodine-123 and
Cardiac Adrenergic Activity in Familial
Dilated Cardiomyopathy
Elisabete Martins, MD,* Ana Oliveira, MD,† José Silva-Cardoso, MD, PHD,*§
Teresa Faria, MD,† Teresa Pinho, MD,* Manuel Campelo, MD,* Anto´nio Madureira, MD,‡
Orquı´dea Ribeiro, BSC, Isabel Ramos, MD, PHD,‡ Jorge G. Pereira, MD,†
Francisco Rocha-Gonçalves, MD, PHD§
Porto, Portugalamilial dilated cardiomyopathy (FDCM) is
characterized by genetic heterogeneity, in-
complete age-dependent penetrance, and a
multifactorial pathogenesis (1). Diagnosis is
still dependent on clinical criteria and familial
investigation (2). On the other hand, several abnor-
malities have been described among asymptomatic
relatives, such as isolated left ventricle (LV) en-
largement (3). These abnormalities could assist in
identifying affected relatives, who are potential can-
didates for early therapeutic interventions. How-
ever, currently not even the presence of such abnor-
malities allows inferring carrier state or future
progression of the disease. We hypothesized that
See page 964
meta-iodobenzylguanidine iodine-123 (123I-mIBG)
imaging, a tool for monitoring sympathetic activity,
could be useful in the evaluation of family members,
as it reflects pathophysiologic mechanisms involved in
disease progression (4). This evaluation could provide
prognostic data useful in this clinical setting.
We evaluated 45 FDCM members from 23
families defined by the European Society of Cardi-
ology criteria (2); 25 patients (56%) were male, with
a median age of 43 years (interquartile range, 36 to
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2010, accepted July 7, 2010.51 years). One of the families has the disease locus
located in chromosome 7q22.3-31.1 (5). All partic-
ipants underwent 12-lead electrocardiogram and
2-dimensional echocardiogram. Measurements
were done according to the American Society of
Echocardiography. Forty members also underwent
cardiac magnetic resonance (CMR) on a 3-Tesla
scanner (Magneton trio, Siemens AG, Erlangen,
Germany). The protocol included contrast-
enhanced images, acquired 10 to 15 min after
intravenous administration of gadobutrol (Gadovist
[Schering AG, Berlin, Germany]; 0.2 mmol/kg).
The 123I-mIBG imaging was performed after intra-
venous administration of 370 MBq (10 mCi) of
123I-mIBG (4). We used a dual-headed gamma
camera (GE Millennium MG, Haifa, Israel),
equipped with low-energy, high-resolution,
parallel-hole collimators, using a 20% window cen-
tered at the 159-keV photo peak. Images were
processed with dedicated software (QGS/QPS
[Cedars-Sinai Medical Center, Los Angeles, Cali-
fornia] on a Xeleris [Paris, France] workstation).
No attenuation correction was performed. Anterior
projection planar thoracic images were obtained 20
min and 4 h after tracer injection, and heart/
mediastinal (H/M) ratio and myocardial washout
rate (WR) calculated twice by 2 independent
blinded observers. The final results were obtained
by the mean of the average of each operator. A
blood sample was obtained for B-type natriuretic
peptide (BNP) quantification (Architect system,
Abbott, Abbott Park, Illinois) just before 123I-
mIBG administration. Heart rate variability param-
eters were calculated, using a DigiTrack-Plus Re-
corder (Philips Medical Systems, Andover,
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960Massachusetts) and a Philips Zymed
Holter, Model 1810 Plus Software (Phil-
ips Medical Systems). All statistical anal-
yses were performed with SPSS for Win-
dows (version 16.0; SPSS Inc, Chicago,
Illinois). Categorical data were compared
using Fisher exact test. Student t and
Mann-Whitney U tests were used to com-
pare continuous variables. The Spearman
correlation was used to evaluate associa-
tions in continuous variables with asym-
metric distribution, such as LV mass index
and LV ejection fraction (EF).
Twenty-nine familial members (64%) had EF
50% (DCM patients), and 16 had EF 50%,
ncluding 6 with reverse remodeling (previous LV
ystolic dysfunction) and 10 asymptomatic relatives.
n expected difference between both groups was
bserved in CMR-indexed LV end-diastolic vol-
mes (134 ml/m2 [range 100 to 161] vs. 85 ml/m2
range 73 to 95]; p  0.001), LVEF (30% [range
5% to 45%] vs. 55% [range 55% to 64%];
 0.001), right ventricular EF (48  10% vs. 55 
%; p  0.017), late hyperenhancement (8 patients
s. none; p  0.035), plasma BNP (104 pg/ml
range 18 to 354 pg/ml] vs. 10 pg/ml [range 10 to
LV
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Figure 1. Comparison Between FDCM Patients and Relatives Ac
(A) Cardiac magnetic resonance (CMR) left ventricular (LV) end-dias
delayed hyperenhancement, (D) plasma B-type natriuretic peptide (
washout rate (WR), (F) 123I-mIBG late heart to mediastinum activity
§Mann-Whitney U test. FDCM  familial dilated cardiomyopathy; LVEF6 pg/ml]; p  0.001], myocardial WR (43  11%
s. 34  9%; p  0.011), and late H/M ratio (1.73
0.26 vs. 1.89  0.14; p  0.027) (Fig. 1). No
eart variability parameter value was distinct be-
ween both groups. We did not find significant
ifferences in WR value and late H/M ratio be-
ween members with (47.2  11.3% and 1.6 [range
.4 to 1.8], respectively) and without (40.2 11.3%
nd 1.7 [range 1.6 to 1.9], respectively) delayed
yperenhancement on CMR (p  0.16 and p 
.22, respectively). The majority (55%) of DCM
atients were in New York Heart Association
unctional class I, and 90% were treated with
eta-blockers. In this group, WR was higher than
0% (2 SDs) in 24 (83%), and late H/M was
nferior to 1.7 in 11 patients (38%). Myocardial
R and late H/M ratio were both correlated with
NP (r  0.595, p  0.01; r  0.622, p  0.01)
Fig. 2), LVEF (r  0.668, p  0.01; r  0.685,
 0.01), LV diastolic (r  0.677, p  0.01; r 
0.584, p  0.01), and systolic (r  0.743, p 
.01; r  0.660, p  0.01) indexed volumes and
V indexed mass (r  0.638, p  0.01; r 
0.471, p  0.05) on CMR imaging. In the group
ith normal LV systolic function, we found an
bnormally high myocardial WR (30%) in 11
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Figure 2. Relationship of Plasma BNP to Cardiac 123I-mIBG Scintigraphy Data
123Correlations between plasma BNP levels and (A) myocardial I-mIBG WR and (B) late H/M. Abbreviations as in Figure 1.Figure 3. Characterization of Familial DCM Members Using Different Imaging Methods
Illustrative examples of (A) 2-dimensional echocardiogram, (B) cardiac magnetic resonance, and (C) 123I-mIBG scan images of: 1) a patient
with dilated cardiomyopathy (DCM) and late hyperenhancement; 2) a patient with reverse remodeling and left bundle branch block; and
3) an identiﬁed carrier with preserved left ventricular ejection fraction. 123I-mIBG parameters: 1) late H/M  1.6, WR  41.6%; 2) late
H/M  1.9, WR  36%; 3) late H/M  1.8, WR  40.2%. Abbreviations as in Figure 1.
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962articipants (69%), including 5 with reverse remod-
ling, 4 of 5 identified carriers, and 2 relatives with
ormal echocardiograms and unknown carrier state
Fig. 3). We did not find correlations between
yocardial 123I-mIBG WR and LVEF or indexed
olumes or mass. However, 123I-mIBG WR was
orrelated with normalized low-frequency power
r  0.691, p  0.01) and low-frequency/high-
requency ratio (r  0.702, p  0.01) heart rate
ariability parameters. During 558 days (range 432
o 863 days) of follow-up, 6 patients (21%) were
ubmitted to heart transplantation. WR was signif-
cantly different between DCM patients who did
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ardiac 123I-mIBG Scintigraphy Parameters in
bers
tion of scintigraphic parameters according to left ventricular
ction (EF) of family members. Dilated cardiomyopathy (DCM)
lation with occurrence of heart transplantation during follow-up.
ith EF 50%: relation with carrier state of asymptomatic mem-
vidence of reverse remodeling among patients. (B) Distribution of
EF according to late H/M; relation with the presence of delayed
ncement in cardiac magnetic resonance. Abbreviations as in51  10%) and did not (41  11%) undergo transplantation (p  0.05), as was the presence of
ate hyperenhancement on CMR (p  0.02) (Fig.
). None of those with EF 50% developed or had
orsening of heart failure symptoms in this time
nterval.
Our study provides evidence of the heterogeneity
f 123I-mIBG findings between FDCM members
with known and unknown disease). We did find
apid WR in a high percentage of individuals with
ormal EF, and this may reflect the increased
drenergic drive related to the cardiac remodeling
rocess. This hypothesis was somewhat corrobo-
ated by the presence of an elevated WR in indi-
iduals with reverse remodeling and in 4 locus
isease carriers who, theoretically, have higher risk
or DCM development. In relatives with EF
50%, a rapid WR could reflect specific his-
opathologic base or particular gene/protein in-
olvement that causes major interference with car-
iac sympathetic nerve metabolism; alternatively, it
ould reflect the decreased contractility of cardiac
yocytes, eventually detected by other diagnostic
ools. Late H/M ratio, an index of sympathetic
enervation, is usually altered with more severe
eart failure, so it is not expected to be significantly
hanged at early stages of FDCM. In the preserved
ystolic function group, we did not obtain correla-
ions between WR and LV volumes. This result
ould be dependent on sample size or just reflecting
he great heterogeneity of sympathetic drive be-
ween individuals, even with identical LV dimen-
ions and systolic function. We found a positive
orrelation between WR and 2 heart variability
ndexes related to sympathetic activity only in the
roup of patients with EF 50%; this could reflect
hanges of the sympathovagal balance throughout
ifferent stages of disease, as already pointed out by
ther investigators.
Because of the small number of patients in this
tudy and the short-term follow-up, we cannot
valuate the prognostic value of the 123I-mIBG
cintigraphy parameters. These parameters could
dd complementary information to other morpho-
unctional imaging studies, guiding the start of early
edical treatment or the clinical follow-up schedule
f asymptomatic relatives.
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